XILONE FORTE SYRUP; prednisolone, anti inflammatory agents .
ACTIVE-INGREDIENT OF XILONE FORTE SYRUP
Each 5 ml contains: Prednisolone (as sodium phosphate) 15 mg.
INDICATION OF XILONE FORTE SYRUP
Prednisolone is indicated in the following conditions: – Endocrine disorders : Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, nonsuppurative throiditis, hypercalemia associated with cancer. – Rheumatic disorders: As adjunctive therapy for short-term administration in : Psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute non-specific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. – Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of : Systemic lupus erythematosus, acute rheumatic carditis. – Dermatologic diseases: Pemphigus, Bullous dermatitis herpetiformis, severe erythema multiforme (stevens-johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis. – Allergic states: Control of severe or incapacitating allergic conditions : Seasonal or perennial allergic rhinitis, bronchial asthma, contact dermatitis , atopic dermatitis, serum sickness, drughypersensitivity reactions. – Ophthalmicus, diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers, Herpes zoster ophthalmicus, anterior segment inflammation, diffuse posterior uveitis and choroiditis, sympathetic ophthamia, allergic conjunctivitis, keratitis, chorioretinitis, optic neuritis, iritis and iridocyclitis. – Respiratory diseases: Symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis, fluminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis.- Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anaemia. – Neoplastic diseases: For pallivative management of : leukemias and lymphomas in adults, acute leukemia of childhood. – Edematous states: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of yhe idiopathic type or that due to lupus erythematosus. – Gastrointestinal diseases: To tide the patient over a critical periodof the disease in : Ulcerative colitis, regional enteritis. – Miscellaneous: Tuberculous meningitis with subarachnoid block or impainding block used concurrently with appropriate antituberculous chemotherapy. Teichinosis with neurologic or myocardial involvement. In addition to the above indications Prednisolone is indicated for systemic dermatomyositis (polymyositisw), kidney transplant rejection or kidney transplant rejection prophylaxis.
DOSAGE OF XILONE FORTE SYRUP
Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet
Ask your pharmacist or doctor for help if you do not understand the instructions on the box .
The recommended dose is : –
Dosage of prednisolone should be individualized according to the severity of the disease and the response of the patient. For infants and children, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight. Dosage should be decreased or discontinued gradually when the drug has been administered for more than a few days. If a period of spontaneous remission occurs in a chronic condition, treatment should be discontinued. The initial dosage of prednisolone may be vary from 5 mg to 60 mg per day. depending on the specific disease entity being treated . In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. Adults: 5 – 60 mg daily as a single dose or in divided doses. Children : Acute asthma : 1-2 mg/kg once daily or divided on 2 equal doses for 3 – 10 days (maximum 60 mg/day). Anti-inflammatory or immunosuppressive : 0.14 – 2 mg/kg daily in 3 – 4 divided doses.
OVER-DOSAGE OF XILONE FORTE SYRUP
CONTRA-INDICATION OF XILONE FORTE SYRUP
Systemic fungal infections. Hypersensitivity to the drug.
STORAGE OF XILONE FORTE SYRUP
PACK OF XILONE FORTE SYRUP
A bottle containing 100 ml Xilone Forte Syrup.
XILONE FORTE SYRUP MANUFACTURED BY
EUROPEAN EGYPTIAN PHARMACEUTICAL INDUSTRIES ALEXANDRIA-EGYPT
There are no reviews yet.